Posted by Michael Wonder on 06 Apr 2020
India has cut off half the supply of a potential coronavirus treatment touted by Trump
6 April 2020 - Nearly half the supply of hydroxychloroquine to the U.S. comes from makers in India, a flow that has now been abruptly stanched after the Asian nation banned exports of all forms of the malaria drug touted by President Donald Trump as a “game changer” for treating the coronavirus.
According to data compiled by Bloomberg Intelligence, 47% of the U.S. supply of the drug last year came from India makers.
Only a handful of suppliers in the top 10 are non-Indian, such as Actavis, now a subsidiary of Israeli generics giant Teva Pharmaceutical Industries It’s likely that some of their production facilities are nevertheless located in India, the biggest maker of generic drugs in the world.
